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Introduction {#sec1}
============

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia, insulin resistance, and insufficient insulin secretion from islet β cells ([@bib40]). However, it is becoming increasingly apparent that over-secretion of glucagon from pancreatic α cells also contributes to the increased hepatic glucose production and associated hyperglycemia in T2DM. The abnormalities in glucagon secretion in T2DM include both loss of adequate suppression under hyperglycemic conditions ([@bib12], [@bib13], [@bib14], [@bib19], [@bib15], [@bib67]) and insufficient release during episodes of hypoglycemia ([@bib20], [@bib7], [@bib63]).

Despite the centrality of glucagon in the etiology of T2DM, the mechanisms by which glucagon secretion is regulated at low glucose have not been fully elucidated. Several paracrine processes have been demonstrated to alter glucagon secretion ([@bib22], [@bib24], [@bib25], [@bib10], [@bib26]). However, in low glucose, glucagon secretion is controlled by mechanisms intrinsic to the α cell ([@bib68], [@bib69]).

The β cell is tailored to deal with conditions of high glucose: the high-K~m~ GLUT transporter (GLUT2), high-K~m~ glucokinase, and high respiratory capacity in β cells result in a robust insulin secretory response to hyperglycemia ([@bib27], [@bib28], [@bib18]). In the α cell, glucokinase activity ([@bib28]) and glycolytic flux ([@bib27]) are comparable with that of β cells. However, glucose oxidation ([@bib62], [@bib17]), as well as glucose-induced ATP ([@bib17], [@bib32], [@bib58], [@bib42]), FADH~2~ ([@bib54]), and NAD(P)H ([@bib55]) production are all lower in α cells. Despite α cells having a lower capacity to produce ATP in response to glucose, α cells are still able to retain secretory function at low or even in the complete absence of glucose ([@bib16], [@bib49], [@bib60], [@bib68]).

Some tissues have an obligatory need for glucose as an energy substrate ([@bib5]). However, many tissues in the body act as "omnivores" using a variety of carbon substrates as energy sources to sustain sufficient ATP generation. β-oxidation of free fatty acids (FFAs) is a major energy source in the heart ([@bib46], [@bib44]), muscle ([@bib57]), and liver ([@bib50]). In the islet, FFAs are known to regulate glucose-induced insulin secretion independently of β-oxidation via G-protein-coupled receptor GPR40 signaling ([@bib33]). In the α cell, less is known about the role of FFAs in regulating glucagon secretion. Although short-term exposure to supra-physiological levels of FFA have been demonstrated to increase glucagon secretion ([@bib48]), this may be due to GPR40 signaling ([@bib38]), rather than β-oxidation. Circulating FFAs are essential for maintaining systemic energy homeostasis during hypoglycemia ([@bib29]). Given that β-oxidation of FFAs can provide substantial amounts of ATP, it may be that α cells utilize this energy source, oxidizing FFAs to maintain secretory function in conditions of hypoglycemia.

Here, we show that the oxidation of long-chain FFAs in α cells contributes to maintaining glucagon secretion under hypoglycemic conditions. We also provide a mechanism by which fatty acid oxidation (FAO) energizes glucagon secretion in counter-regulatory conditions.

Results {#sec2}
=======

Glucagon Secretion from Mouse α Cells Depends on FAO {#sec2.1}
----------------------------------------------------

We first explored the dependence of glucagon secretion under hypoglycemic conditions on FAO ([Figure 1](#fig1){ref-type="fig"}). Carnitine palmitoyltransferase 1 (CPT1) is a mitochondrial transmembrane enzyme responsible for the formation of acyl-carnitine from long-chain acyl-coenzyme A\'s (CoA), which can subsequently be transported into the mitochondria and used for β-oxidation. This enzyme is considered rate limiting for β-oxidation of long-chain fatty acids (LCFAs; [@bib36], [@bib65]). When mouse islets were exposed to low (1 mM) glucose, pharmacological blockade of CPT1 with etomoxir (100 μM) reduced glucagon secretion by ∼40% (p \< 0.001; [Figure 1](#fig1){ref-type="fig"}A) and decreased the cytoplasmic ATP/ADP ratio (p \< 0.0001; [Figure 1](#fig1){ref-type="fig"}B). This was via a direct effect on α cells, because insulin signaling was not altered (p = 0.84; [Figure S1](#mmc1){ref-type="supplementary-material"}). Etomoxir also reduced glucagon secretion by ∼40% in αTC1-6 cells at 1 mM glucose (p = 0.005; [Figure 1](#fig1){ref-type="fig"}C). This was due to a ∼40% reduction in β-oxidation (p = 0.017; [Figure 1](#fig1){ref-type="fig"}D). These data show that FAO contributes to glucagon secretion in hypoglycemic conditions.Figure 1Blocking FFA Transport Pharmacologically or by CPT1a Knockdown Reduces Glucagon Secretion in Mouse α Cells and αTC1-6 Cells(A) Glucagon secretion from WT mouse islets at 1 and 10 mM glucose with or without etomoxir (100 μM) reduced glucagon secretion (n = 3 mice).(B) ATP production in WT mouse islets during exposure to 1 or 10 mM glucose, as well as 1 mM glucose and etomoxir (100 μM) (n = 4 mice).(C) Glucagon secretion from αTC1-6 cells at 1 and 10 mM glucose with or without etomoxir (100 μM) (n = 3).(D) β-Oxidation measured using \[^3^H\]palmitate in αTC1-6 cells at 1 and 10 mM glucose with or without etomoxir (100 μM) (n = 6 observations, from 2 experiments).All data are represented as mean ± SEM. Paired t test with Tukey post hoc or two-way ANOVA with Student-Newman-Keuls post hoc; ^∗^p \< 0.05. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

CPT1a is Essential for Fat Oxidation and Glucagon Secretion in α Cells {#sec2.2}
----------------------------------------------------------------------

We investigated the expression of CPT1 in α cells and found a high degree of co-localization between glucagon and the liver CPT1 isoform (CPT1a) in wild-type (WT) mouse islets ([Figure 2](#fig2){ref-type="fig"}A). The muscle CPT1 isoform (CPT1b) is also known to be expressed in α cells, but to a lower degree than CPT1a ([@bib6]). Knockdown of *Cpt1a* in αTC1-6 cells (40% reduced protein content; [Figure 2](#fig2){ref-type="fig"}B) resulted in a decrease in glucagon secretion (p = 0.003; [Figure 2](#fig2){ref-type="fig"}C) and β-oxidation (p = 0.033; [Figure 2](#fig2){ref-type="fig"}D) at 1 mM glucose, consistent with our pharmacological blockade of CPT1 with etomoxir ([Figure 1](#fig1){ref-type="fig"}).Figure 2Knockout of CPT1a Specifically in α Cells Reduces Glucagon Secretion(A) Immunofluorescence for glucagon (red) and CPT1a (green) in WT mouse islets from pancreatic slides. Scale bar, 50 μM.(B) Knockdown (KD) of CPT1a in αTC1-6 cells treated with either scrambled small interfering RNA (siRNA; control) or siRNA targeting *Cpt1a* mRNA (note the ∼40% reduction) (n = 6 observations from 3 experiments).(C) Glucagon secretion in αTC1-6 cells at 1 and 10 mM glucose treated with either scrambled siRNA (control) or siRNA targeting *Cpt1a* mRNA (n = 3).(D) β-Oxidation measured using \[^3^H\]palmitate in αTC1-6 cells at 1 and 10 mM glucose treated with either scrambled siRNA (control) or siRNA targeting *Cpt1a* mRNA (n = 6 observations, from 2 experiments).(E) Immunofluorescent detection of glucagon (red) and CPT1a (green) in isolated islets from α cell-specific knockout of *Cpt1*a (αCPT1a-KO) and littermate control mice. Scale bar, 50 μM (n = 5).(F) Percentage (%) of cells that show co-localization of CPT1a and glucagon in αCPT1a-KO mice (n = 5 islets, 3 mice, 145 cells).(G) Glucagon content in isolated islets from control and αCPT1a-KO (KO) islets (n = 6).(H) Glucagon secretion from isolated islets from control and αCPT1a-KO mice at 1 and 10 mM glucose (n = 6).(I) Glucagon secretion during perfusion in control (n = 3) and αCPT1a-KO (n = 3) mice at 4, 6, and 10 mM glucose.(J) Average glucagon secretion from control (n = 3) and αCPT1a-KO mice (n = 3) at 4, 6, and 10 mM glucose, calculated from the last 8--10 min in each condition. Two-way ANOVA with post hoc: ^\#^p \< 0.05 versus control; ^∗^p \< 0.05 versus 4 mM glucose.Paired t test with Tukey post hoc or two-way ANOVA; ^∗^p \< 0.05. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

The αTC1-6 cell line is an artificial system, and so to understand the implications of reduced CPT1a expression in whole islets, we generated an α cell-specific *Cpt1a* knockout (αCPT1a-KO) mouse. Islets from these mice have no CPT1a expression in 85% ± 2% of the α cells ([Figures 2](#fig2){ref-type="fig"}E and 2F). Knockout of *Cpt1a* reduced glucagon secretion by ∼40% at 1 mM glucose (p \< 0.001; [Figure 2](#fig2){ref-type="fig"}H), without affecting glucagon content (p = 0.937; [Figure 2](#fig2){ref-type="fig"}G) or glucagon secretion at 10 mM glucose (p = 0.64; [Figure 2](#fig2){ref-type="fig"}H). Insulin secretion was not affected by the loss of *Cpt1a* in α cells (p = 0.43; [Figure S1](#mmc1){ref-type="supplementary-material"}B). Blood glucose is unlikely to reach 1 mM *in vivo*; therefore, we investigated glucagon secretion *in situ* from control and αCPT1a-KO by perfusion of the whole pancreas with 4, 6, and 10 mM glucose. Glucagon secretion from αCPT1a-KO was significantly lower compared with control mice (p = 0.003; [Figures 2](#fig2){ref-type="fig"}I and 2J), and only control mice responded by significantly lowering glucagon secretion in response to 10 mM glucose (p = 0.045; [Figures 2](#fig2){ref-type="fig"}I and 2J). These data suggest that *Cpt1a* knockout reduces glucagon secretion from mouse islets in conditions of hypoglycemia.

*Cpt1a* Knockout Reduces Fasting Plasma Glucose {#sec2.3}
-----------------------------------------------

To test whether FAO contributes to the counter-regulatory response to hypoglycemia *in vivo*, we measured plasma glucose and glucagon in αCPT1a-KO mice ([Figure 3](#fig3){ref-type="fig"}). Knockout of *Cpt1a* did not change fed plasma glucose (p = 0.669; [Figure 3](#fig3){ref-type="fig"}A), glucagon (p = 0.608; [Figure 3](#fig3){ref-type="fig"}B), or hepatic protein content of the gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK; p = 0.999) and glucose 6-phosphatase (G6PC; p = 0.25; [Figures 3](#fig3){ref-type="fig"}C and 3D). Following a 4-hr fast, plasma glucose was decreased in αCPT1a-KO mice compared with control mice (p = 0.03; [Figure 3](#fig3){ref-type="fig"}E). Despite plasma glucose being lower in αCPT1a-KO compared with control mice following a 4-hr fast, plasma glucagon was no different between the two genotypes (p = 0.987; [Figure 3](#fig3){ref-type="fig"}F). In line with previous studies ([@bib2]), 4 hr of fasting seemed to reduced plasma glucagon in the fed state in both αCPT1a-KO and control mice. The change in plasma glucagon relative to the fed state was greater in αCPT1a-KO compared with control mice (p = 0.029; [Figure 3](#fig3){ref-type="fig"}G), indicating a change in the regulation of circulating glucagon levels. We next tested whether ketone body metabolism could contribute to the maintenance of glucagon secretion in WT islets during hypoglycemia. Treating WT islets with 3-hydroxybuterate (0.5 mM) reduced glucagon secretion at 1 mM glucose (p = 0.0002; [Figure S1](#mmc1){ref-type="supplementary-material"}J). This is in agreement with studies from perfused rat pancreas and human subjects ([@bib30], [@bib53]) where glucagon secretion was decreased or unaffected by ketones bodies. It is therefore unlikely that ketone metabolism in α cells of the αCPT1a-KO mice could have compensated for the reduced FAO. In support of this, the concentration of fasted plasma ketone bodies was not different in αCPT1a-KO and control mice (p = 0.21; [Figure 3](#fig3){ref-type="fig"}H). These data demonstrate that FAO in α cells may contribute to maintaining blood glucose during a 4-hr fast, and that this response is impaired in αCPT1a-KO mice.Figure 3*Cpt1a* Knockout Reduces Fasting Plasma Glucose(A) Plasma glucose in fed control and αCPT1a-KO (KO) mice (n = 14 ).(B) Plasma glucagon in fed control and KO mice (n = 4--5).(C) Representative blots of PEPCK, G6PC, and calnexin in fed control and KO mice.(D) Protein content of hepatic PEPCK and G6PC in fed control and KO mice (n = 3--5).(E) Plasma glucose in control and KO mice following a 4-hr fast (n = 10--12).(F) Plasma glucagon in control and KO mice following a 4-hr fast (n = 4--5).(G) Difference between 4 hr fasted and fed plasma glucagon in control and KO mice (n = 4--5).(H) Plasma ketone bodies in control and KO mice following a 4-hr fast (n = 7--9).All data are represented as mean ± SEM. Paired t test with Tukey post hoc; ^∗^p \< 0.05. ns, not significant. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Disruption of FAO Changes Electrical Activity in α Cells {#sec2.4}
--------------------------------------------------------

α cells are electrically active, utilizing these electrical signals to drive glucagon secretion ([@bib4], [@bib22], [@bib45], [@bib34], [@bib56], [@bib69], [@bib26]). Given that inhibition of FAO decreased glucagon secretion ([Figure 2](#fig2){ref-type="fig"}), we hypothesized that this was due to an effect on α cell membrane potential.

Inhibition of FAO resulted in a reduction in action potential (AP) amplitude in mouse α cells ([Figure 4](#fig4){ref-type="fig"}). Etomoxir (100 μM) reduced AP amplitude (p \< 0.0001; [Figures 4](#fig4){ref-type="fig"}A--4D) and depolarized the minimum membrane potential by 7 mV (p \< 0.001; [Figure 4](#fig4){ref-type="fig"}E). Etomoxir also reduced the amplitude of intracellular Ca^2+^ oscillations ([Figure S2](#mmc1){ref-type="supplementary-material"}). The effect of pharmacological blockade of FAO on membrane potential in α cells was mirrored in αCPT1a-KO mice ([Figures 4](#fig4){ref-type="fig"}F--4M). α cells from αCPT1a-KO mice had a lower AP amplitude compared with control mice (p \< 0.0001; [Figure 4](#fig4){ref-type="fig"}H). Minimal membrane potential in αCPT1a-KO mice was depolarized compared with controls (p = 0.026; [Figure 4](#fig4){ref-type="fig"}I). The frequency of AP firing was not changed (p = 0.94; [Figure 4](#fig4){ref-type="fig"}J), suggesting that disruption of FAO reduces glucagon secretion by reducing AP amplitude, rather than firing frequency. High glucose (\>6 mM) is known to decrease glucagon secretion by reducing AP amplitude in α cells by ∼17 mV ([@bib69]). Consistent with this, in control mice, high glucose (10 mM) decreased AP amplitude by 12 ± 2 mV compared with 1 mM glucose (p = 0.014; [Figure 4](#fig4){ref-type="fig"}K). In contrast, 10 mM glucose did not decrease AP amplitude in αCPT1a-KO mice (p = 0.94). Furthermore, the reduction in AP amplitude in αCPT1a-KO at 1 mM glucose was significantly greater than in control islets due to 10 mM glucose (p = 0.005). Therefore, the suppression of AP amplitude by FAO disruption is physiologically significant.Figure 4Disruption of FFA Transport by CPT1a Reduces Action Potential Amplitude in Mouse α Cells(A) Electrical activity in WT α cell at 1 mM glucose with or without etomoxir (100 μM) (10 islets from 6 mice).(B) Average action potential waveform for (A), in etomoxir compared with 1 mM glucose, measured over the entire experimental condition.(C) Expanded view on 1 mM glucose and etomoxir conditions for (A).(D) Action potential amplitude in WT α cells at 1 mM glucose with or without etomoxir (100 μM) (10 islets from 6 WT mice).(E) Minimum membrane potential (V~MIN~) in WT α cells at 1 mM glucose with or without etomoxir (100 μM) (10 islets from 6 mice).(F) Electrical activity in control α cell at 1 mM glucose.(G) Electrical activity in αCPT1a-KO α cell at 1 mM glucose.(H) Action potential amplitude in α cells from αCPT1a-KO compared with control at 1 mM glucose (8 control islets for 4 mice and 13 αCPT1a-KO islets for 4 mice).(I) Minimal potential (V~MIN~) in α cells from αCPT1a-KO mice compared with control at 1 mM glucose (8 control islets for 4 mice and 13 αCPT1a-KO islets for 4 mice).(J) Firing frequency in control and αCPT1a-KO islets at 1 mM glucose (8 control islets for 4 mice) and 13 αCPT1a-KO islets for 4 mice).(K) Action potential amplitude in α cells from control and αCPT1a-KO islets at 1 and 10 mM glucose (6 control islets for 4 mice and 6 αCPT1a-KO islets for 4 mice).(L) Action potential amplitude in α cells from αCPT1a-KO islets at 1 mM glucose with or without etomoxir (100 μM) (3 islets from 3 mice for each genotype).(M) Raster plots demonstrating robust action potentials in 5 control α cells, and weaker action potentials in 5 α cells from αCPT1a-KO islets.Paired t test with Tukey post hoc; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Disruption of FAO Alters α Cell Membrane Potential via a K~ATP~-Independent Mechanism {#sec2.5}
-------------------------------------------------------------------------------------

We investigated whether the effect of CPT1 inhibition was due to a decrease in K~ATP~ channel conductance (G~KATP~). First, we noted that our pharmacological data ([Figure 4](#fig4){ref-type="fig"}) appeared incompatible with a K~ATP~-dependent mechanism because etomoxir decreased intracellular ATP (*\[ATP\]*~*i*~) ([Figure 1](#fig1){ref-type="fig"}B), which would result in an increase in G~KATP~, consequently hyperpolarizing the membrane. Nevertheless, because the K~ATP~ channel is crucial to glucagon secretion ([@bib45], [@bib69]), we wanted to investigate the dependence (if any) of the effect on K~ATP~ channel activity.

We measured G~KATP~ in response to inhibition of CPT1a ([Figure 5](#fig5){ref-type="fig"}). Unexpectedly, inhibition of CPT1a with etomoxir ([Figure 5](#fig5){ref-type="fig"}A; p = 0.73; 100 μM) or by gene knockout ([Figure 5](#fig5){ref-type="fig"}C; p = 0.85) did not change G~KATP~ in α cells. Because β cells have a larger G~KATP~ ([@bib8]), we used them to further interrogate any pharmacological effects of etomoxir on G~KATP~ ([Figures 5](#fig5){ref-type="fig"}E--5H). Etomoxir did not change G~KATP~ in β cells at low glucose (p = 0.96). We mimicked the effects of etomoxir on *\[ATP\]*~*i*~ by artificially decreasing *\[ATP\]*~*i*~. To this end, we continuously monitored G~KATP~ in standard whole cell while diluting the cell interior with a pipette solution containing 1 mM ATP ([Figures 5](#fig5){ref-type="fig"}I--5M). This would achieve a bona fide decrease in *\[ATP\]*~*i*~ because the ATP concentration in α cells at 1 mM glucose is \>1 mM ([@bib17]). Decreasing *\[ATP\]*~*i*~ in this way did not change G~KATP~ in α cells (p = 0.93; [Figures 5](#fig5){ref-type="fig"}I and 5L), consistent with what has been shown in β cells ([@bib66]). In a final set of experiments, we applied etomoxir in the presence of the K~ATP~ channel inhibitor tolbutamide (100 μM; [Figure 5](#fig5){ref-type="fig"}N). In these experiments, when the α cells were repolarized by injection of negative currents, etomoxir was still able to depolarize the membrane potential (p = 0.001; [Figure 5](#fig5){ref-type="fig"}O) and reduce AP amplitude (p = 0.042; [Figure 5](#fig5){ref-type="fig"}P). This effect of etomoxir must be independent of K~ATP~ channel closure. In conclusion, blockade of FAO via inhibition of CPT1 depolarizes the α cell membrane potential by a K~ATP~ channel-independent mechanism.Figure 5Inhibition of CPT1a Disrupts α Cell Membrane Potential via a K~ATP~-Independent Mechanism(A) G~KATP~ in wild-type (WT) mouse α cells at 1 mM glucose with or without etomoxir (100 μM) (6 islets, 5 mice).(B) Holding current in WT mouse α cells at 1 mM glucose with or without etomoxir (100 μM) (11 islets, 6 mice).(C) G~KATP~ in α cells from αCPT1a-KO mice compared with control at 1 mM glucose (8 control islets from 4 mice and 13 αCPT1a-KO islets from 4 mice).(D) Holding current in α cells from αCPT1a-KO mice compared with control at 1 mM glucose (8 control islets for 4 mice and 13 αCPT1a-KO islets for 4 mice).(E) Electrical activity in WT β cell at 1 mM glucose with or without etomoxir (100 μM) and at 20 mM glucose.(F) G~KATP~ in WT β cell at 1 mM glucose with or without etomoxir (100 μM) and at 20 mM glucose.(G) Grouped data of V~M~ recording in β cells following etomoxir and 20 mM glucose application (6 islets from 6 WT mice).(H) Grouped data of G~KATP~ recording in β cells following etomoxir and 20 mM glucose application (6 islets from 6 WT mice).(I) To mimic the effects of etomoxir in 1 mM glucose on *\[ATP\]*~*i*~, we artificially reduced *\[ATP\]*~*i*~ by setting the pipette concentration (1 mM) to be lower than the putative *\[ATP\]*~*i*~ in 1 mM glucose (\>1 mM; [@bib17]) and measured G~KATP~. The arrow denotes when whole cell was achieved, which initiates the run-down of *\[ATP\]*~*i*~ from the endogenous concentration to the pipette concentration.(J) Holding current (I~hold~) from (I).(K) G~KATP~ and I~hold~ after 0, 1, and 3 min of whole-cell recording (I).(L) Grouped data, recording G~KATP~ during artificial run-down of *\[ATP\]*~*i*~ (4 WT islets, 4 mice).(M) Grouped data, recording I~hold~ during artificial run-down of *\[ATP\]*~*i*~ (4 WT islets, 4 mice).(N) Membrane potential recording from a WT α cell. Tolbutamide was applied to maximally open K~ATP~ channels. A negative current was then injected to hyperpolarize the α cell. Etomoxir was still able to depolarize α cells.(O) Grouped data for change in minimum potential (V~MIN~) (n = 8 islets, n = 4 mice).(P) Grouped data for change in action potential amplitude (n = 8 islets, n = 4 mice).Paired t test with Tukey post hoc or two-way ANOVA; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

We therefore sought an ATP-dependent mechanism that could explain these data: namely, result in a depolarization of membrane potential, following a decrease in *\[ATP\]*~*i*~. It can be seen that there was an increase in the holding current (the current required to hold the membrane potential at −70 mV) following pharmacological inhibition of CTP1 (p = 0.008; [Figure 5](#fig5){ref-type="fig"}B), knockout of *Cpt1a* (p = 0.017; [Figure 5](#fig5){ref-type="fig"}D), or by artificially reducing *\[ATP\]*~*i*~ in 1 mM glucose ([Figures 5](#fig5){ref-type="fig"}J--5M; p = 0.049).

FFA Oxidation Maintains α Cell Membrane Potential and Glucagon Secretion by Energizing the Na^+^-K^+^ Pump {#sec2.6}
----------------------------------------------------------------------------------------------------------

The Na^+^-K^+^ pump is an ATPase, extruding intracellular Na^+^ in exchange for K^+^. Its operation is electrogenic and generates an outward current. Thus, reduced activity of the Na^+^-K^+^ pump would account for the increase in holding current following inhibition of CPT1a ([Figures 5](#fig5){ref-type="fig"}B and 5D). We therefore postulated that membrane potential and AP amplitude are maintained in low (1 mM) glucose because FAO energizes the Na^+^-K^+^ pump.

To investigate this, we exposed islets from WT mice to 0.5 mM ouabain in 1 mM glucose ([Figure 6](#fig6){ref-type="fig"}). Blockade of Na^+^-K^+^ pump activity decreased AP amplitude (p = 0.0005; [Figures 6](#fig6){ref-type="fig"}A--6D). Ouabain also reduced glucagon secretion in low glucose (p = 0.0015; [Figure 6](#fig6){ref-type="fig"}G), but did not change G~KATP~ in α cells ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E) or β cells (p = 0.45; [Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G). Thus, this depolarization was not due to a reduction in G~KATP~. Ouabain did, however, increase the magnitude of the holding current in both α cells (p = 0.0132; [Figure 6](#fig6){ref-type="fig"}F) and β cells (p = 0.0242; [Figure S1](#mmc1){ref-type="supplementary-material"}H). Therefore, all of the effects of FAO inhibition on electrical activity ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}) were mirrored by blockade of the Na^+^-K^+^ pump with ouabain. Together, these data suggest that Na^+^-K^+^ pump activity is high in low glucose, and preservation of this activity by FAO maintains a hyperpolarized membrane potential, and therefore AP amplitude and glucagon secretion, in α cells. To test the consistency of our experimental observations with this theory, we constructed a mathematical model of membrane potential in α cells ([Figures 6](#fig6){ref-type="fig"}H and 6I). Reducing energy supply to the Na^+^-K^+^ pump from FAO in the model recapitulated the experimental data, supporting our hypothesis.Figure 6FFA Oxidation Maintains α Cell Membrane Potential by Energizing the Na^+^-K^+^ Pump(A) Electrical activity in a WT α cell in response to 1 mM glucose with or without ouabain (0.5 mM).(B) Average action potential waveform for (A) during 1 mM glucose and ouabain, measured over entire experimental condition.(C) Expanded view on 1 mM glucose and ouabain conditions for (A).(D) Grouped data for change in action potential amplitude in response to 1 mM glucose with or without ouabain (0.5 mM; 7 islets, 4 WT mice).(E) Grouped data for change in minimum membrane potential (V~MIN~) in WT α cells in response to 1 mM glucose with or without ouabain (0.5 mM; 7 islets, 4 WT mice).(F) The holding current in absolute value in WT α cells, in response to 1 mM glucose with or without ouabain (0.5 mM; 7 islets, 4 WT mice).(G) Glucagon secretion from WT islets at 1 and 10 mM glucose with or without ouabain (0.5 mM; n = 4 mice).(H) Mathematical model of α cell electrical activity demonstrates that a reduction of Na^+^-K^+^ pump activity (I~pump~) reduces action potential amplitude, mimicking blockade of CPT1a.(I) Accompanying model of glucagon secretion demonstrates that this results in a reduction of glucagon secretion, also mimicking blockade of CPT1a.All data are represented as mean ± SEM. Paired t test with Tukey post hoc or two-way ANOVA with Student-Newman-Keuls post hoc; ^∗^p \< 0.05. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Reduced FAO in Human Islets Causes a Reduction in Electrical Activity and Glucagon Secretion {#sec2.7}
--------------------------------------------------------------------------------------------

Islets from human donors stained positive for CPT1a, with co-localization (∼90%) of glucagon and CPT1a ([Figure 7](#fig7){ref-type="fig"}A). Inhibition of FAO with etomoxir (100 μM) suppressed glucagon secretion at 1 mM glucose (p = 0.008; [Figure 7](#fig7){ref-type="fig"}B). Finally, analysis of membrane potential in α cells revealed that etomoxir reduces AP amplitude (p = 0.034; [Figures 7](#fig7){ref-type="fig"}C--7E) and depolarizes the membrane (p = 0.035; [Figure 7](#fig7){ref-type="fig"}F). These observations recapitulate our findings in mouse islets and suggest that FAO in human α cells contributes to the maintenance of membrane potential and glucagon secretion in low glucose conditions.Figure 7CPT1a Blockade in Human Islets Reduces α Cell Membrane Potential and Glucagon Secretion(A) Immunofluorescent detection of glucagon (red) and CPT1a (green) in isolated human islets (scale bar, 50 μm).(B) Glucagon secretion from human islets at 1 and 10 mM glucose with or without etomoxir (100 μM) reduced glucagon secretion (n = 3 donors).(C) Electrical activity in human α cells at 1 mM glucose with or without etomoxir (100 μM) (n = 3 donors, ≤7 cells).(D) Expanded view of 1 mM glucose and etomoxir conditions for (C).(E) Action potential amplitude in human α cells at 1 mM glucose with or without etomoxir (100 μM) and at 10 mM glucose (n = 3 donors, ≤7 cells).(F) Minimum potential in human α cells at 1 mM glucose with or without etomoxir (100 μM) and at 10 mM glucose (n = 3 donors, ≤7 cells).All data are represented as mean ± SEM. Paired t test with Tukey post hoc or two-way ANOVA with Student-Newman-Keuls post hoc; ^∗^p \< 0.05.

Discussion {#sec3}
==========

In this study we investigated the role of FAO in regulating glucagon secretion under hypoglycemic conditions. We found that pharmacological blockade or knockout of CPT1a profoundly reduced glucagon secretion from mouse islets at low glucose. These findings were mirrored in human islets with pharmacological inhibition of CPT1. In both mouse and human α cells, inhibition of CPT1 was associated with membrane potential depolarization and reduced AP amplitude.

Our findings suggest that during fasting, when blood glucose becomes low, fatty acids play a significant role in maintaining blood glucose by sustaining basal glucagon secretion. We show that FAO contributes to ATP production in low glucose conditions in α cells, and that this FFA-derived ATP maintains glucagon secretion by energizing the Na^+^-K^+^ pump. We propose that in low glucose concentrations, ATP generated by FAO is an essential energy supply for the Na^+^-K^+^ pump, keeping the α cell membrane sufficiently repolarized to prevent voltage-dependent inactivation of the ion channels involved in AP firing, thus allowing the generation of large-amplitude APs. When glucose becomes available, ATP derived from glucose oxidation triggers membrane depolarization by closure of K~ATP~ channels, leading to a K~ATP~-dependent reduction in glucagon secretion.

The K~ATP~ channel has been demonstrated to mediate the intrinsic regulation of glucagon secretion from α cells ([@bib45], [@bib69]). According to this model of counter-regulation, a reduction in glucose concentrations causes opening of K~ATP~ channels, a hyperpolarization of membrane potential, an increase in AP amplitude, and, therefore, glucagon secretion. However, this model is not wholly accepted (see [@bib24], [@bib25], [@bib26]). In low glucose, we observed that inhibition or reduction of FAO depolarized α cells and decreased glucagon secretion. If this depolarizing effect of inhibiting FAO were mediated by changes in K~ATP~ channel activity, we would expect to observe a reduction in K~ATP~ conductance. However, this is incompatible with our data because inhibition of FAO decreases *\[ATP\]*~*i*~, which would cause an increase in K~ATP~ conductance. Furthermore, we did not observe a change in K~ATP~ conductance in response to CPT1a inhibition, either pharmacologically or via knockout, suggesting that K~ATP~ channels are not directly involved.

To identify a possible mechanism underlying the effect on α cell electrical activity, we considered energy-consuming cellular mechanisms that result in membrane depolarization following a reduction in cellular ATP. The Na^+^-K^+^ pump is a major energy consumer in most types of cells (∼10% in muscle ([@bib52]), ∼40% in neurons ([@bib3]), and ∼50% in the kidney ([@bib11]), utilizing more ATP than any other enzyme and consuming 19%--28% of whole-body ATP ([@bib59]). The α cell appears to be no exception; we show that the application of the Na^+^-K^+^ pump inhibitor ouabain robustly depolarizes α cells. Considering that the Na^+^-K^+^ pump has a K~m~ of ∼0.4 mM for ATP ([@bib35]), α cell pump activity at 1 mM glucose would be drastically decreased when ATP levels are further reduced. Furthermore, this K~m~ is 30 times higher than the K~m~ of the K~ATP~ channel to ATP ([@bib66], [@bib35]). The pump would therefore turn off before the channel would be affected by the reduction in *\[ATP\]*~*i*~. We suggest that the reduction in ATP, which occurs when FAO is blocked with etomoxir or when *Cpt1a* is knocked out in α cells, leads to a reduction in Na^+^-K^+^ pump activity in low glucose.

Defects in mitochondrial β-oxidation have serious clinical consequences ([@bib37]) and account for a major cause of hypoglycemic seizures. There are at least 12 FAO disorders described, of which 10 are associated with routine fasting hypoglycemia ([@bib23]). CPT1a deficiency presents in infancy, is characterized by hypoketotic hypoglycemia ([@bib47], [@bib21]), and is treated with frequent feedings to prevent prolonged fasting ([@bib43]).

It has previously been suggested that the liver uses ATP generated from FAO to maintain glucose production ([@bib64], [@bib39]). However, recent findings suggest that hepatic FAO is expendable for maintaining 24-hr fasting blood glucose ([@bib41]). Thus, loss of CPT1a activity in the liver of CPT1a-deficient patients may cause the hypoketonemia, but not the hypoglycemia. Our data support this and indicate that the hypoglycemia in these patients may be caused by a loss of FAO in the α cell and, consequently, reduced glucagon secretion.

Experimental Procedures {#sec4}
=======================

All animal experiments were conducted in accordance with the UK Animals Scientific Procedures Act (1986) and University of Oxford ethical guidelines, and were approved by the local Ethical Committees. Human pancreatic islets were isolated (with ethical approval and clinical consent) at the Diabetes Research and Wellness Foundation Human Islet Isolation Facility (OCDEM, Oxford, UK) from pancreases of six non-diabetic donors. Donors were on average 61 years old (range 25--76) with a BMI of 24 (range 19.3--30) and HbA1c of 5.5% (range 5.3--5.9). Three of six donors were female.

Animals and Generation of αCPT1a-KO Mice {#sec4.1}
----------------------------------------

C57BL/6j mice were used as WT mice in this study. To generate αCPT1a-KO, mice carrying a loxP insert flanking exons 11 and 12 of the *Cpt1a* gene ([@bib61]) were crossed with mice carrying Cre recombinase under the control of the proglucagon promoter ([@bib51]). Mice homozygous for the loxP allele were used as controls and are referred to as such.

*In Vivo* Measurements of Plasma Glucose, Glucagon, and Ketone Body Concentration {#sec4.2}
---------------------------------------------------------------------------------

Plasma glucose, glucagon, and ketone body measurements were conducted *in vivo* on αCPT1a-KO and control mice in response to fasting. Mice were restrained, and a tail-vein sample of plasma was used to measure fed plasma glucose and ketone bodies. Mice were then individually caged for the 4-hr fasting period and given unrestricted access to water during this time. At the end of the fasting period, mice were restrained and a tail-vein sample of plasma was used to measure plasma glucose and ketone bodies. Mice were then culled by cervical dislocation and trunk plasma collected. The serum was then removed and stored at −80°C. Serum samples were used to measure plasma glucagon. Measurements were conducted using a dual mouse insulin/glucagon assay system (Meso Scale Discovery, MD, USA), according to the manufacturer's protocol.

Isolation of Pancreatic Islets {#sec4.3}
------------------------------

Mice at 12--16 weeks of age were killed by cervical dislocation (Schedule 1 procedure). Pancreatic islets were isolated by Liberase digestion followed by manual picking. Islets were used acutely and were, pending the experiments, maintained in tissue culture for \<24 hr in RPMI 1640 (11879-020; GIBCO, Thermo Fisher Scientific) containing 1% penicillin/streptomycin (1214-122; GIBCO, Thermo Fisher Scientific), 10% fetal bovine serum (FBS; F7524-500G; Sigma-Aldrich), and 7.5 mM glucose before the measurements.

Hormone Release Measurements {#sec4.4}
----------------------------

Measurements of insulin and glucagon secretion were performed using sequential incubations of isolated mouse and human islets as described in the [Supplemental Information](#app2){ref-type="sec"}.

Electrophysiology {#sec4.5}
-----------------

All electrophysiological measurements were performed at 33°C to 34°C on α cells within intact islets (from αCPT1a-KO mice, littermate controls, WT C57BL/6j mice, and human islets). Membrane potential and whole-cell K~ATP~-current recordings were conducted using the perforated patch technique, as previously described ([@bib16]). The composition of solutions is described in the [Supplemental Information](#app2){ref-type="sec"}.

ATP Imaging {#sec4.6}
-----------

The ATP/ADP sensor Perceval was used, as previously described ([@bib1]).

FFA Oxidation Measurements {#sec4.7}
--------------------------

αTC1-6 cells were cultured overnight in RPMI culture medium containing 5 mM glucose. On the day of the experiment, the cells were incubated in 0 mM glucose Krebs Ringer buffer (KRB) with or without etomoxir. The cells were then exposed to 0.3 mM palmitate containing 0.22 MBq \[^3^H\]palmitate for 1 hr. The supernatant was then subjected to a Falkes extraction and the aqueous phase assayed for H^3^ content. From this, β-oxidation was calculated and normalized to cell count. Further details are in the [Supplemental Information](#app2){ref-type="sec"}.

Mathematical Model of α Cell Membrane Potential {#sec4.8}
-----------------------------------------------

A mathematical model of Na^+^-K^+^ pump activity was added to a model of α cell membrane potential ([@bib9]) and simulated in the simulation environment NEURON with a 25-μS time step. The model is further described in the [Supplemental Information](#app2){ref-type="sec"}.

Statistical Tests {#sec4.9}
-----------------

All data are reported as mean ± SEM, unless otherwise stated. Statistical significance was defined as p \< 0.05. All statistical tests were conducted in Prism (GraphPad Software, San Diego, CA, USA). For two groupings, a t test was conducted with the appropriate post hoc test. For more than two groupings, a one-way ANOVA was conducted. If there were two independent variables, a two-way ANOVA was conducted. If the data passed normality criteria (D'Agostino's test of normality and Bartlett's test of equal variances), a parametric test was conducted with the appropriate post hoc test (Tukey or Student-Neumann-Keuls). If the normality criteria were not met, a Kruskal-Wallis test with Dunn's multiple comparison test was conducted.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures and Figures S1 and S2Document S2. Article plus Supplemental Information
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